ジャーナル: Cell Rep Med / 年: 2026 タイトル: A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein. 著者: Alexandra A Abu-Shmais / Luqiang Guo / Ahmed Magdy Khalil / Sabina E Leonard / Rose J Miller / Alexis K Janke / Matthew J Vukovich / Lindsay E Bass / Yukthi P Suresh / Scott A Rush / Rachael ...著者: Alexandra A Abu-Shmais / Luqiang Guo / Ahmed Magdy Khalil / Sabina E Leonard / Rose J Miller / Alexis K Janke / Matthew J Vukovich / Lindsay E Bass / Yukthi P Suresh / Scott A Rush / Rachael M Wolters / Nurgun Kose / Robert H Carnahan / James E Crowe / Rachel H Bonami / Jarrod J Mousa / Jason S McLellan / Ivelin S Georgiev / 要旨: Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are frequent drivers of morbidity and mortality in susceptible populations. The primary target of neutralizing antibodies is ...Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are frequent drivers of morbidity and mortality in susceptible populations. The primary target of neutralizing antibodies is the fusion (F) glycoprotein on the surface of the RSV and hMPV virion. As a result of the structural conservation between RSV and hMPV F, three antigenic regions are known to induce cross-neutralizing responses: sites III, IV, and V. Leveraging LIBRA-seq, we identify five RSV/hMPV cross-reactive human antibodies. One antibody, RM 5-1, potently neutralizes all tested viruses from the major subgroups of RSV and hMPV and provides protection against RSV and hMPV in a mouse challenge model. Structural analysis reveals that RM 5-1 utilizes an uncommon genetic signature to bind an epitope that spans sites Ø, II, and V. These findings highlight the molecular and structural elements influencing RSV and hMPV cross-reactivity as well as the potential of antibody RM 5-1 for translational development.
履歴
登録
2024年6月18日
登録サイト: RCSB / 処理サイト: RCSB
改定 1.0
2025年5月28日
Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: EM metadata / Data content type: EM metadata / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: Additional map / Part number: 1 / Data content type: Additional map / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: FSC / Data content type: FSC / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: Half map / Part number: 1 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: Half map / Part number: 2 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: Image / Data content type: Image / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: Mask / Part number: 1 / Data content type: Mask / Provider: repository / タイプ: Initial release
改定 1.0
2025年5月28日
Data content type: Primary map / Data content type: Primary map / Provider: repository / タイプ: Initial release
Data content type: EM metadata / Data content type: EM metadata / EM metadata / Group: Database references / Experimental summary / Data content type: EM metadata / EM metadata / EM metadata / カテゴリ: citation / citation_author / em_admin Data content type: EM metadata / EM metadata ...EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata / EM metadata Item: _citation.country / _citation.journal_abbrev ..._citation.country / _citation.journal_abbrev / _citation.journal_id_CSD / _citation.journal_id_ISSN / _citation.journal_volume / _citation.page_first / _citation.page_last / _citation.pdbx_database_id_DOI / _citation.pdbx_database_id_PubMed / _citation.title / _citation.year / _em_admin.last_update